Valuation : Intervacc AB

Market Cap 349M 36.02M 31.03M 29.38M 26.63M 49.97M 3.44B 50.22M 134M 1.75B 135M 132M 5.53B P/E 2026 *
-0.91x
P/E 2027 * -0.91x
Enterprise Value 260M 26.83M 23.12M 21.89M 19.84M 37.22M 2.56B 37.41M 99.98M 1.3B 101M 98.56M 4.12B EV / Sales 2026 *
12.4x
EV / Sales 2027 * 9.6x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week-7.75%
Current month-3.40%
1 month-16.07%
3 months-24.15%
6 months+40.08%
Current year+10.82%
1 week 1
Extreme 1
1.06
1 month 1
Extreme 0.999
1.2
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/23/25 Free

Chief Financial Officer

929,208 1.2269%
2/17/25 Buy

Chief Executive Officer

135,000 0.1783%
2/17/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-7.75%-10.96%-74.62% 36.02M
-2.11%-1.68%+43.40%+95.58% 66.93B
-0.23%-4.45%+32.50%+77.58% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
-1.05%-4.43%+28.84%+12.17% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+0.43%-3.37%+16.22%-17.48% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
-1.94%-4.94%-8.15%+519.85% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average -0.31%-3.43%+26.49%+215.75% 27.05B
Weighted average by Cap. -0.56%-2.83%+31.25%+172.01%

Financials

2026 *2027 *
Net sales 21M 2.17M 1.87M 1.77M 1.6M 3.01M 207M 3.02M 8.08M 105M 8.14M 7.96M 333M 30M 3.1M 2.67M 2.53M 2.29M 4.3M 296M 4.32M 11.54M 150M 11.63M 11.37M 476M
Net income -82.45M -8.51M -7.33M -6.94M -6.29M -11.8M -813M -11.86M -31.71M -414M -31.96M -31.26M -1.31B -83.65M -8.63M -7.44M -7.04M -6.38M -11.98M -825M -12.04M -32.17M -420M -32.42M -31.71M -1.33B
Net Debt -89M -9.19M -7.91M -7.49M -6.79M -12.74M -878M -12.81M -34.22M -446M -34.5M -33.74M -1.41B -61M -6.3M -5.42M -5.14M -4.66M -8.73M -601M -8.78M -23.46M -306M -23.64M -23.12M -967M
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-09-11 SEK 1.024 -0.39% 96,338
26-09-10 SEK 1.028 +0.78% 158,595
26-09-09 SEK 1.020 -1.35% 276,823
26-09-08 SEK 1.034 -3.18% 336,695
26-09-07 SEK 1.068 -3.78% 186,399

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!